Sign in or create an account to add this stock to your watchlist.
About biOasis Technologies (OTCMKTS:BIOAF)
biOasis Technologies Inc., a development stage biopharmaceutical company, researches, develops, and commercializes technologies and products for the treatment of central nervous system and brain diseases. It develops and commercializes Transcend and Transcendpep platforms for the delivery of therapeutic compounds across the blood-brain barrier and into the central nervous system for the treatment of brain cancers, neurodegenerative, and metabolic diseases. biOasis Technologies Inc. has a collaborative research agreement with CQDM and Brain Canada to perform research on the delivery of therapeutic compounds across the blood-brain barrier; and a research collaboration agreement with Brigham and Women's Hospital Inc., as well as a license agreement with Vaccinex Inc. The company was incorporated in 2006 and is headquartered in Richmond, Canada.
Industry, Sector and Symbol
Industry Drugs, proprietaries, & sundries
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / Sales70.25
Price / CashN/A
Book Value$0.01 per share
Price / Book53.00
EPS (Most Recent Fiscal Year)N/A
Return on Equity-139.01%
Return on Assets-115.81%
biOasis Technologies (OTCMKTS:BIOAF) Frequently Asked Questions
What is biOasis Technologies' stock symbol?
biOasis Technologies trades on the OTCMKTS under the ticker symbol "BIOAF."
When is biOasis Technologies' next earnings date?
Who are some of biOasis Technologies' key competitors?
Who are biOasis Technologies' key executives?
biOasis Technologies' management team includes the folowing people:
- Dr. Mark Day, CEO, Pres, Chief Scientist & Director
- Dr. Wilfred A. Jefferies D.Phil. (Oxon), Scientific Founder and Chairman of Scientific Advisory Board (Age 60)
- Mr. Christopher P. Lowe M.B.A., Chief Financial Officer and Board Advisor (Age 47)
- Ms. Catherine London, Exec. VP and Head of Corp. Communications & Investor Relations
- Mr. Kim Elton, Director of Marketing
Has biOasis Technologies been receiving favorable news coverage?
Press coverage about BIOAF stock has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. biOasis Technologies earned a daily sentiment score of 0.11 on Accern's scale. They also gave news stories about the company an impact score of 46.86 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
How do I buy shares of biOasis Technologies?
Shares of BIOAF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is biOasis Technologies' stock price today?
One share of BIOAF stock can currently be purchased for approximately $0.53.
How big of a company is biOasis Technologies?
biOasis Technologies has a market capitalization of $27.11 million and generates $390,000.00 in revenue each year.
How can I contact biOasis Technologies?
biOasis Technologies' mailing address is 10691 SHELLBRIDGE WAY SUITE 130, RICHMOND A1, V6X 2W8. The company can be reached via phone at 604-295-7014 or via email at [email protected]
MarketBeat Community Rating for biOasis Technologies (BIOAF)MarketBeat's community ratings are surveys of what our community members think about biOasis Technologies and other stocks. Vote "Outperform" if you believe BIOAF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOAF will underperform the S&P 500 over the long term. You may vote once every thirty days.
biOasis Technologies (OTCMKTS:BIOAF) Analyst Ratings History
(Data available from 5/22/2016 forward)
biOasis Technologies (OTCMKTS:BIOAF) Earnings History and Estimates Chart
biOasis Technologies (OTCMKTS BIOAF) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|6/27/2018|| || || || || || || || |
|10/31/2017||Q2 2018||($0.02)||$0.12 million||View||N/A|
|7/31/2017||Q1 2018||($0.01)||$0.16 million||View||N/A|
|6/28/2017||Q4 2017||($0.01)||$0.08 million||View||N/A|
|1/30/2017||Q3 2017||($0.01)||$0.10 million||View||N/A|
|10/28/2016||Q2 2017||($0.02)||$0.09 million||View||N/A|
|7/29/2016||Q1 2017||($0.02)||$0.12 million||View||N/A|
|6/28/2016||Q4 2016||($0.01)||$0.10 million||View||N/A|
|1/28/2016||Q3 2016||($0.01)||$0.05 million||View||N/A|
biOasis Technologies (OTCMKTS:BIOAF) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
biOasis Technologies (OTCMKTS BIOAF) Insider Trading and Institutional Ownership History
biOasis Technologies (OTCMKTS BIOAF) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
biOasis Technologies (OTCMKTS BIOAF) News Headlines
biOasis Technologies (OTCMKTS:BIOAF) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
biOasis Technologies (OTCMKTS BIOAF) Stock Chart for Tuesday, May, 22, 2018